Sapacitabine: Additional Ph III SEAMLESS data

The open-label, international Phase III SEAMLESS trial in 491 newly diagnosed AML patients ages ≥70 years who were not candidates for, or who refused, intensive induction chemotherapy showed that alternating cycles of sapacitabine and Dacogen decitabine

Read the full 369 word article

How to gain access

Continue reading with a
two-week free trial.